Over the past few years, STING (stimulator of interferon genes) receptors have emerged as pivotal activators of both innate and adaptive immune responses against cancer through the activation of the interferon (IFN) signaling pathway.[1] A common therapeutic strategy for leveraging the STING pathway involves the direct delivery of agonists to tumor sites. This evidence concerns the gene STING1 and neoplasm.